Alcon axes eye program

Alcon announced late Friday that it was ending its evaluation of anecortave acetate for age-related macular degeneration. The Swiss company says that an analysis of the data demonstrated no effect on the primary or secondary endpoints. Release | Report

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.